Cholecystokinin-2 Receptor Agonist 177Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma – Results of the Lumed Phase 0a Study

Rottenburger C1, Nicolas GP1, McDougall L1, Kaul F1, Cachovan M2, Vija AH3, Schibli R4, Geistlich S5, Schumann A6, Rau T7, Glatz K8, Behe M5, Christ ER9, Wild D1.

J Nucl Med. 2019 Sep 13. pii: jnumed.119.233031. doi: 10.2967/jnumed.119.233031.

  1. Division of Nuclear Medicine, University Hospital Basel, Switzerland.
  2. Siemens Healthcare GmbH, Forchheim, Germany, Germany.
  3. Molecular Imaging, Siemens Medical Solutions USA, Inc., Hoffman Estates, IL, USA, United States.
  4. Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, ETH, Switzerland.
  5. Center for Radiopharmaceutical Sciences, Paul Scherrer Institute, Switzerland.
  6. 3B Pharmaceuticals GmbH, Germany.
  7. Institute of Pathology, University of Bern, Switzerland.
  8. Institute of Pathology, University Hospital Basel, Switzerland.
  9. Division of Endocrinology, Diabetology and Metabolism, University Hospital Basel, Switzerland.